Market intelligence
All coverage
Market Analysis: Friday’s tame CPI print soothed immediate rate-cut concerns and spurred a relief rally. Futures lifted all sectors, but tech/AI remains a focus.…
Oracle’s spectacular AI-driven rally has turned choppy in recent days. After rocketing to all-time highs in September reuters.com, profit-taking set in. The stock plunged…
Procter & Gamble’s Q1 report beat expectations across the board. Revenue of $22.39 billion and core EPS of $1.99 both topped consensus marketscreener.com. In…
Normally the SSA announces the annual COLA in mid-October after the Bureau of Labor Statistics releases the September Consumer Price Index for Urban Wage…
Microsoft’s Azure cloud has been the standout. In FY2025 Azure revenue surpassed $75B, growing ~34% ts2.tech ts2.tech. Analysts note Azure continues to accelerate: in…
As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run. The stock has surged ~28% on Oct 23…
In summary, AMD’s recent AI-driven surge has been fueled by heavyweight partnerships and robust demand, earning plaudits from executives and analysts alike. But the…
Genenta’s Oct. 24 announcement ignited optimism. According to the official press release, Anemocyte will incorporate Genenta’s clinically validated LVV plasmid DNA platform into its…
Plug Power’s share price has been on a roller-coaster. After languishing around $1.50 in late summer 2025, the stock surged to a new 52-week…
Market Snapshot: In recent days Ambev stock has been flat-to-up. On Oct 24 it traded near $2.20 reuters.com, close to its recent five-week low…
In late October 2025, IonQ’s share price was around $60 after a tumultuous run. The stock peaked near $82 on Oct. 13 – a…
CrowdStrike’s stock has climbed sharply in October. After trading near $484 in mid-October, the share price jumped into the $520s by Oct 23 investing.com.…
On Oct. 23, Palantir Technologies and Lumen Technologies unveiled a “multi-year, multi-million-dollar” strategic partnership to fuse Palantir’s AI/data platform with Lumen’s high-speed networking. According…
Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic…
Broadcom’s recent stock rally has been led by blockbuster AI deals. The centerpiece is an OpenAI collaboration announced on Oct. 13, 2025: Broadcom will…
SMCI shares fell about 8% on Oct. 23 after Super Micro said Q1 revenue would be ~$5 billion, down from a prior $6–7 billion…
